Search research articles
Contact Us
Filters
Showing results (141-150 of 173) with videos related to
Page
of 18
Sort By:
Annals of Hematology
|
October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
M Feuring-Buske, M Kneba, M Unterhalt, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 30, 2020
Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance
M Oertel, K Elsayad, R Engenhart-Cabillic, et al.
International Journal of Cancer
|
May 16, 1996
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice
R Schnell, A A Katouzi, C Linnartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
P J Bröckelmann, H Müller, O Casasnovas, et al.
Blood
|
September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
B Coiffier, C Haioun, N Ketterer, et al.
Cancer Chemotherapy and Pharmacology
|
May 31, 2013
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
T H Han, R Chen, R Advani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18
C-A Voltin, H Goergen, C Baues, et al.
Nuklearmedizin. Nuclear Medicine
|
February 4, 2010
Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies
Markus Dietlein, S M Börner, T Fischer, et al.
British Journal of Cancer
|
January 17, 2013
Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
K Behringer, H Müller, H Görgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment
U Rueffer, K Breuer, A Josting, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 173) with videos related to
Sort By:
Page
of 18
Annals of Hematology
|
October 24, 2000
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
M Feuring-Buske, M Kneba, M Unterhalt, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 30, 2020
Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance
M Oertel, K Elsayad, R Engenhart-Cabillic, et al.
International Journal of Cancer
|
May 16, 1996
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice
R Schnell, A A Katouzi, C Linnartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
P J Bröckelmann, H Müller, O Casasnovas, et al.
Blood
|
September 10, 1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
B Coiffier, C Haioun, N Ketterer, et al.
Cancer Chemotherapy and Pharmacology
|
May 31, 2013
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
T H Han, R Chen, R Advani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18
C-A Voltin, H Goergen, C Baues, et al.
Nuklearmedizin. Nuclear Medicine
|
February 4, 2010
Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies
Markus Dietlein, S M Börner, T Fischer, et al.
British Journal of Cancer
|
January 17, 2013
Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group
K Behringer, H Müller, H Görgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment
U Rueffer, K Breuer, A Josting, et al.
Page
of 18